CY1111423T1 - Αναστολεις ns5b hcv - Google Patents
Αναστολεις ns5b hcvInfo
- Publication number
- CY1111423T1 CY1111423T1 CY20111100016T CY111100016T CY1111423T1 CY 1111423 T1 CY1111423 T1 CY 1111423T1 CY 20111100016 T CY20111100016 T CY 20111100016T CY 111100016 T CY111100016 T CY 111100016T CY 1111423 T1 CY1111423 T1 CY 1111423T1
- Authority
- CY
- Cyprus
- Prior art keywords
- suspensions
- hcv
- compounds
- ns5b hcv
- ns5b
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Η εφεύρεση περιλαμβάνει ενώσεις του Τύπου (Ι) καθώς και συνθέσεις και μεθόδους χρήσης των ενώσεων. Οι ενώσεις είναι δραστικές έναντι του ιού της υπατίτιδας Γ(HCV) και είναι χρήσιμες στη θεραπεία όσων έχουν προσβληθεί από τον HCV.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77139106P | 2006-02-08 | 2006-02-08 | |
EP07763294A EP1987038B1 (en) | 2006-02-08 | 2007-02-07 | Hcv ns5b inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111423T1 true CY1111423T1 (el) | 2015-08-05 |
Family
ID=38234480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100016T CY1111423T1 (el) | 2006-02-08 | 2011-01-04 | Αναστολεις ns5b hcv |
Country Status (17)
Country | Link |
---|---|
US (1) | US7456165B2 (el) |
EP (1) | EP1987038B1 (el) |
JP (1) | JP5147731B2 (el) |
KR (1) | KR20080102161A (el) |
CN (1) | CN101379066B (el) |
AT (1) | ATE483712T1 (el) |
AU (1) | AU2007211988B2 (el) |
CY (1) | CY1111423T1 (el) |
DE (1) | DE602007009646D1 (el) |
DK (1) | DK1987038T3 (el) |
ES (1) | ES2352574T3 (el) |
HR (1) | HRP20100672T1 (el) |
NO (1) | NO20083513L (el) |
PL (1) | PL1987038T3 (el) |
PT (1) | PT1987038E (el) |
SI (1) | SI1987038T1 (el) |
WO (1) | WO2007092888A2 (el) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1688420A4 (en) * | 2003-11-19 | 2008-10-22 | Japan Tobacco Inc | 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR |
US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
US7399758B2 (en) * | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7521441B2 (en) * | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7521442B2 (en) * | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7456167B2 (en) * | 2006-05-25 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7452876B2 (en) * | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7541351B2 (en) * | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7541352B2 (en) * | 2007-02-02 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7517872B2 (en) * | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7998951B2 (en) * | 2007-03-05 | 2011-08-16 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
US7547690B2 (en) * | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US7541353B2 (en) * | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7538102B2 (en) * | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US7521444B2 (en) * | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7538103B2 (en) * | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US8476257B2 (en) | 2007-12-19 | 2013-07-02 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
EP2280978B1 (en) * | 2008-03-27 | 2013-04-24 | Bristol-Myers Squibb Company | Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors |
US8431568B2 (en) | 2008-03-27 | 2013-04-30 | Bristol-Myers Squibb Company | Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors |
WO2009120745A1 (en) * | 2008-03-27 | 2009-10-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
JP2011515496A (ja) * | 2008-03-27 | 2011-05-19 | ブリストル−マイヤーズ スクイブ カンパニー | ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンhcvns5b阻害剤 |
US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
SG172848A1 (en) | 2009-01-07 | 2011-08-29 | Scynexis Inc | Cyclosporine derivative for use in the treatment of hcv and hiv infection |
JP2012517468A (ja) * | 2009-02-11 | 2012-08-02 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎治療のための化合物 |
US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
EP2459211A1 (en) | 2009-07-31 | 2012-06-06 | Medtronic, Inc. | Continuous subcutaneous administration of interferon- to hepatitis c infected patients |
CA2822357A1 (en) | 2010-12-22 | 2012-06-28 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
WO2012092411A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc. | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
CN103534256B (zh) | 2010-12-30 | 2016-08-10 | 益安药业 | 大环丙型肝炎丝氨酸蛋白酶抑制剂 |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
CN102276531A (zh) * | 2011-05-30 | 2011-12-14 | 扬子江药业集团广州海瑞药业有限公司 | 一种甲磺酸非诺多泮的制备方法 |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
CN104447952A (zh) * | 2014-12-11 | 2015-03-25 | 上海唐润医药科技有限公司 | 丙肝病毒蛋白酶抑制剂及其合成方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040138109A1 (en) * | 2002-09-30 | 2004-07-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Potent inhibitor of HCV serine protease |
EP2332935A1 (en) * | 2003-04-11 | 2011-06-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20050119318A1 (en) * | 2003-10-31 | 2005-06-02 | Hudyma Thomas W. | Inhibitors of HCV replication |
ATE428714T1 (de) | 2004-02-24 | 2009-05-15 | Japan Tobacco Inc | Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor |
US7348425B2 (en) | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
DE502005002697D1 (de) | 2004-10-13 | 2008-03-13 | Merck Patent Gmbh | Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs |
EP1807397A2 (en) | 2004-10-26 | 2007-07-18 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Tetracyclic indole derivatives as antiviral agents |
GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
-
2007
- 2007-02-06 US US11/671,753 patent/US7456165B2/en active Active
- 2007-02-07 JP JP2008554485A patent/JP5147731B2/ja not_active Expired - Fee Related
- 2007-02-07 ES ES07763294T patent/ES2352574T3/es active Active
- 2007-02-07 DE DE602007009646T patent/DE602007009646D1/de active Active
- 2007-02-07 EP EP07763294A patent/EP1987038B1/en active Active
- 2007-02-07 SI SI200730453T patent/SI1987038T1/sl unknown
- 2007-02-07 PL PL07763294T patent/PL1987038T3/pl unknown
- 2007-02-07 PT PT07763294T patent/PT1987038E/pt unknown
- 2007-02-07 KR KR1020087021812A patent/KR20080102161A/ko not_active Application Discontinuation
- 2007-02-07 AT AT07763294T patent/ATE483712T1/de active
- 2007-02-07 CN CN2007800049834A patent/CN101379066B/zh not_active Expired - Fee Related
- 2007-02-07 AU AU2007211988A patent/AU2007211988B2/en not_active Ceased
- 2007-02-07 WO PCT/US2007/061768 patent/WO2007092888A2/en active Application Filing
- 2007-02-07 DK DK07763294.1T patent/DK1987038T3/da active
-
2008
- 2008-08-13 NO NO20083513A patent/NO20083513L/no not_active Application Discontinuation
-
2010
- 2010-12-06 HR HR20100672T patent/HRP20100672T1/hr unknown
-
2011
- 2011-01-04 CY CY20111100016T patent/CY1111423T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
NO20083513L (no) | 2008-10-14 |
EP1987038A2 (en) | 2008-11-05 |
ATE483712T1 (de) | 2010-10-15 |
JP5147731B2 (ja) | 2013-02-20 |
AU2007211988B2 (en) | 2012-02-02 |
US7456165B2 (en) | 2008-11-25 |
CN101379066A (zh) | 2009-03-04 |
HRP20100672T1 (hr) | 2011-01-31 |
AU2007211988A1 (en) | 2007-08-16 |
DK1987038T3 (da) | 2011-01-31 |
SI1987038T1 (sl) | 2011-02-28 |
KR20080102161A (ko) | 2008-11-24 |
WO2007092888A2 (en) | 2007-08-16 |
WO2007092888A3 (en) | 2007-10-11 |
DE602007009646D1 (de) | 2010-11-18 |
JP2009526081A (ja) | 2009-07-16 |
PT1987038E (pt) | 2010-12-09 |
ES2352574T3 (es) | 2011-02-21 |
US20070185083A1 (en) | 2007-08-09 |
PL1987038T3 (pl) | 2011-03-31 |
EP1987038B1 (en) | 2010-10-06 |
CN101379066B (zh) | 2011-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111423T1 (el) | Αναστολεις ns5b hcv | |
ATE469155T1 (de) | Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer | |
DK2209789T3 (da) | Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere | |
EA200802346A1 (ru) | Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с | |
TW200745120A (en) | Indolobenzazepine HCV NS5B inhibitors | |
WO2007140200A3 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
ATE522532T1 (de) | Verbindungen zur behandlung von hepatitis c | |
CY1113752T1 (el) | Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv | |
ATE494291T1 (de) | Verbindungen zur behandlung von hepatitis c | |
MX2010001416A (es) | Compuesto para el tratamiento de la hepatitis c. | |
EA200901241A1 (ru) | Соединения для лечения гепатита с | |
CO6190510A2 (es) | Inhibidores del virus de la hepatitis c | |
MY142240A (en) | Hcv ns3 protease inhibitors | |
TW200745035A (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
MX2009004556A (es) | Inhibidores de la proteasa ns3 del hcv. | |
ATE551343T1 (de) | Tetracyclische verbindungen zur behandlung von hepatitis c | |
EA201000948A1 (ru) | Ингибиторы вирусной полимеразы | |
EA200900298A1 (ru) | Ингибиторы вируса гепатита с | |
ATE505473T1 (de) | Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c | |
UA90909C2 (en) | Hcv ns3 protease inhibitors | |
UA95990C2 (en) | Hcv ns3 protease inhibitors | |
ATE531373T1 (de) | Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren |